tiziana-logo.png
Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement
August 28, 2020 05:30 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted...
tiziana-logo.png
Tiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive Interview
August 27, 2020 02:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted...
tiziana-logo.png
Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseases
August 24, 2020 02:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics...
tiziana-logo.png
Tiziana Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma and other Cancers
August 21, 2020 02:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics...
tiziana-logo.png
Tiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year Term
August 20, 2020 02:00 ET | Tiziana Life Sciences Plc
-          Dr. Ferrara is the discoverer of Avastin® and Lucentis®, multi-billion dollars antibody drugs from Genentech -          A member of National Academy of Sciences and recipient of several...
tiziana-logo.png
Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease
August 18, 2020 02:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics...
tiziana-logo.png
Tiziana Life Sciences to Present at BTIG’s Virtual Biotechnology Conference
August 11, 2020 04:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted...
tiziana-logo.png
Tiziana Life Sciences plc Announces Closing of $57.25 Million Offering
August 05, 2020 11:00 ET | Tiziana Life Sciences Plc
LONDON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics for oncology,...
tiziana-logo.png
Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients
August 04, 2020 02:00 ET | Tiziana Life Sciences Plc
Recently signed agreements with four contract research organizations (“CROs”) to initiate GMP manufacturing, develop inhalation technology, conduct inhalation safety toxicity study in monkeys, and...
tiziana-logo.png
Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million
August 03, 2020 02:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics...